Insider Selling: Santarus CFO Unloads 19,000 Shares of Stock (SNTS)
Santarus (NASDAQ:SNTS) CFO Debra Crawford sold 19,000 shares of the company’s stock on the open market in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $22.38, for a total value of $425,220.00. Following the completion of the sale, the chief financial officer now directly owns 166,326 shares of the company’s stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
A number of analysts have recently weighed in on SNTS shares. Analysts at Leerink Swann downgraded shares of Santarus (NASDAQ:SNTS) from an “outperform” rating to a “market perform” rating in a research note to investors on Thursday, August 22nd. They now have a $26.00 price target on the stock. They noted that the move was a valuation call. Separately, analysts at JMP Securities raised their price target on shares of Santarus (NASDAQ:SNTS) from $27.00 to $31.00 in a research note to investors on Wednesday, August 7th. Finally, analysts at Zacks downgraded shares of Santarus (NASDAQ:SNTS) from an “outperform” rating to a “neutral” rating in a research note to investors on Thursday, July 25th. They now have a $27.80 price target on the stock.
Two research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $25.63.
Santarus (NASDAQ:SNTS) traded down 2.87% on Wednesday, hitting $21.65. The stock had a trading volume of 1,744,007 shares. Santarus has a 1-year low of $8.02 and a 1-year high of $28.10. The stock’s 50-day moving average is $24.45 and its 200-day moving average is $20.84. The company has a market cap of $1.437 billion and a P/E ratio of 15.53.
Santarus (NASDAQ:SNTS) last released its earnings data on Tuesday, August 6th. The company reported $0.94 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.18 by $0.76. The company had revenue of $89.40 million for the quarter, compared to the consensus estimate of $82.90 million. During the same quarter last year, the company posted $0.05 earnings per share. Santarus’s revenue was up 89.4% compared to the same quarter last year. On average, analysts predict that Santarus will post $1.26 earnings per share for the current fiscal year.
Santarus, Inc (NASDAQ:SNTS) is a specialty biopharmaceutical company focused on acquiring, developing and commercializing products that address the needs of patients treated by physician specialists.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.